Sex differences in the executive and behavioral reserve of autosomal dominant frontotemporal dementia
- PMID: 40277045
- PMCID: PMC12022895
- DOI: 10.1002/alz.70070
Sex differences in the executive and behavioral reserve of autosomal dominant frontotemporal dementia
Abstract
Introduction: Self-reported sex influences brain resilience, but its role in genetic frontotemporal dementia (FTD) remains unclear.
Methods: We analyzed 394 genetic-FTD patients and 279 controls from the ALLFTD consortium, assessing annual neuropsychological performance and MRI-based cortical thickness. Clinical characteristics and cortical thickness were compared between sexes. We used the residuals of linear regression models, which predict each participant's cognitive and behavioral performance levels relative to cortical thickness, as a proxy for reserve. We then modeled sex differences in longitudinal trajectories with linear mixed-effects models.
Results: Symptomatic females with genetic FTD had lower frontal cortical thickness than males, and the C9orf72 subgroup showed lower-than-expected frontal cortical thickness for a given level of executive functioning. Differences in cognitive reserve between sexes peaked near symptom onset but diminished thereafter.
Discussion: Females with genetic FTD showed higher cognitive reserve than males, suggesting that self-reported sex modulates resilience to frontotemporal neurodegeneration.
Highlights: Females with genetic FTD showed higher cognitive reserve than males. Those differences were particularly pronounced in the C9orf72 and GRN subgroups. The higher cognitive reserve in females declined as the disease progressed.
Keywords: cognitive reserve; diagnosis; frontotemporal dementia; magnetic resonance imaging; neuroimaging; progression; resilience; survival.
© 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Conflict of interest statement
J.G.C.: Declarations of interest: none; S.R‐G.: Declarations of interest: none; K.B.C.: Declarations of interest: none; J.S.G.: Declarations of interest: none; M.M.: Declarations of interest: none; L.V.‐A.: Declarations of interest: none; A.M.‐N.: Declarations of interest: none; J.A‐I.: Declarations of interest: none; O.D‐I.: Declarations of interest: none; A.B.: Declarations of interest: none; O.B.: Declarations of interest: none; J.F.: Declarations of interest: none; D.A. participated in advisory boards from Fujirebio‐Europe, Roche Diagnostics, Grifols S.A. and Lilly, and received speaker honoraria from Fujirebio‐Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U. and Esteve Pharmaceuticals S.A., and declares a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease); M.C.‐I.: Declarations of interest: none; I.B.: Declarations of interest: none; M. S.‐S.: Declarations of interest: none; M.B.S.S.: Declarations of interest: none; I.S.M.: Declarations of interest: none; H.W.H.: Declarations of interest: none; L.K.F: Declarations of interest: none; K.K.: Declarations of interest: none; A.M.S.: Declarations of interest: none; C.T.: Declarations of interest: none; K.P.R.: Declarations of interest: none; B.B.: Declarations of interest: none; A.B.: Declarations of interest: none; H.J.R.: Declarations of interest: none; A.L. reports holding a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx, EPI8382175.0), and has served as a consultant or on advisory boards for Almirall, Fujirebio‐Europe, Grifols, Eisai, Lilly, Novartis, Nutricia, Roche, Biogen and Zambon; I.I‐G.: Declarations of interest: none. Author disclosures are available in the supporting information.
Figures
References
-
- Boeve BF, Boxer AL, Kumfor F, Pijnenburg Y, Rohrer JD. Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations. Lancet Neurol. 2022;21:258‐272. - PubMed
-
- Goldman J, Farmer J, Wood E, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005;65:1817‐1819. - PubMed
MeSH terms
Substances
Grants and funding
- AG/NIA NIH HHS/United States
- TR/NCATS NIH HHS/United States
- National Institute of Neurological Diseases and Stroke
- NIH-NIA
- CM23/00176/Carlos III National Institute of Health of Spain
- JR20/0018/Carlos III National Institute of Health of Spain
- PI21/00791/Carlos III National Institute of Health of Spain
- INT21/00073/Carlos III National Institute of Health of Spain
- PI20/01473/Carlos III National Institute of Health of Spain
- PI23/01786/Carlos III National Institute of Health of Spain
- CP20/00038/Carlos III National Institute of Health of Spain
- PI22/00307/Carlos III National Institute of Health of Spain
- PI18/00435/Carlos III National Institute of Health of Spain
- PI20/01330/Carlos III National Institute of Health of Spain
- PI21/01395/Carlos III National Institute of Health of Spain
- CM21/00243/Carlos III National Institute of Health of Spain
- European Union
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas Program 1
- Fondo Europeo de Desarrollo Regional
- Unión Europea
- Una Manera de Hacer Europa
- R01 AG056850/NH/NIH HHS/United States
- R21 AG056974/NH/NIH HHS/United States
- R01 AG061566/NH/NIH HHS/United States
- R01 AG081394/NH/NIH HHS/United States
- R61AG066543/NH/NIH HHS/United States
- AG032306/NH/NIH HHS/United States
- K24AG045333/NH/NIH HHS/United States
- AG038791/NH/NIH HHS/United States
- R01AG072475/NH/NIH HHS/United States
- Department de Salut de la Generalitat de Catalunya
- SLT006/17/00119/Pla Estratègic de Recerca I Innovació en Salut
- SLT002/16/00408/Pla Estratègic de Recerca I Innovació en Salut
- IIBSP-DOW-2020-151/Fundación Tatiana Pérez de Guzmán el Bueno
- H2020-SC1-BHC-2018-2020/Horizon 2020-Research and Innovation Framework Programme from the European Union
- AARG-22-923680/Alzheimer Association
- AARF-22-924456/ALZ/Alzheimer's Association/United States
- Jerome Lejeune Foundation postdoctoral fellowship
- CM21/00243″/Instituto de Salud Carlos III through the Río Hortega Fellowship
- UNI/551/2021/European Union. L.V.-A.
- Global Brain Health Institute
LinkOut - more resources
Full Text Sources
Miscellaneous
